Agloe Medical secures Series A funding of hundreds of millions, advancing fully-automated humanoid triple-arm robot for complex spinal surgeries

The proceeds will primarily be used to accelerate the technological iteration of Agloe Medical's spinal surgical robotics platform, promote its clinical application, and further expand into global markets.

For a long time, the market for spinal surgical robots has been intensely competitive and dominated by major players. However, most existing devices adopt a single-arm design, often functioning merely as "needle holders" or "navigation aids." Their limited operational range makes it challenging to handle complex procedures such as decompression and deformity correction. With advancements in medical technology and rising surgical demands, clinical expectations for surgical robots have shifted from them being mere "tools" to becoming "intelligent assistants."

So, how can robots be made to think and operate like experienced surgeons? Agloe Medical's answer is to break through the limitations of the single-arm design by deeply integrating fully automated technology with a humanoid robotic form, thereby creating an orthopedic "surgeon-like expert." Here, "humanoid" does not refer to the robot having a human-like appearance or bipedal structure, but rather to its core robotic arm system achieving an extreme simulation of human upper limb movement logic and enabling fully automated, intelligent operation.

Agloe Medical's self-developed spinal surgical robot innovatively adopts a "Humanoid Three-Arm" design:

This design achieves synchronous, automated execution of "microscopy, bone cutting, and screw placement" through three-arm coordination, significantly enhancing surgical efficiency and accuracy. The robot excels at highly simulating the flexibility of a surgeon's wrist and the fine tactile sensitivity of their fingers, enabling precise control—from macroscopic screw trajectory planning to microscopic bone tissue resection.

By tackling the critical challenges of high-precision tracking and coordinated multi-arm control, the system achieves dynamic sub-millimeter operational precision. This advancement addresses the inefficiencies of traditional single-arm robots—such as the frequent need for instrument changes and limited unilateral operation—making it capable of supporting advanced spinal procedures like decompression and deformity correction.

Moreover, the company's ability to create a closed-loop business model has been a key factor in attracting investor confidence. Agloe Medical has established a comprehensive ecosystem integrating "intelligent devices + innovative consumables." Its supporting range of smart, innovative consumables can deeply synchronize with the surgical robot's navigation system. Through algorithmic iteration, these consumables continuously expand their functional adaptability to various vertebral anatomies and surgical scenarios, thereby enhancing overall surgical precision and efficiency. This model diverges from the traditional "one-time sale" approach of conventional medical device companies, positioning Agloe Medical for more sustainable profitability.

The high technological barriers have directly translated into expedited regulatory approval. In September 2025, Agloe Medical's self-developed "Spinal Surgical Navigation and Positioning System" successfully passed the National Medical Products Administration (NMPA)'s Special Review for Innovative Medical Devices in a single submission, paving a fast track for the product's market launch.

It is reported that Agloe Medical has been a frequent participant in prominent international conferences recently, including the North American Spine Society (NASS) Annual Meeting. With its seamless human-machine interaction experience and various innovative features closely aligned with clinical needs, its products have generated significant interest among overseas expert circles. Industry analysts have noted, "Agloe Medical's transition from a mere 'exhibitor' to a substantive 'supplier,' and its ability to enter developed markets directly with its initial installations, demonstrates that its product capabilities have reached a level where it can compete on the same stage as top international brands."

At the 2025 NASS, the team introduced their related products to physicians and hospital clients from various countries